RxDoctor Payments Data

Dimitrios Farmakiotis, MD

Infectious Disease · Providence, RINPI 1255625919

Payments from drug & device makers

What this record shows

That places this record below the midpoint for infectious disease clinicians in RI, where the typical reported total is $63.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$241,947in research payments, 2019–2025

Across 7 payments — averaging $34,564 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$134K
  • Astrazeneca UK Limited$108K

How this compares

$0 in reported general payments places this provider in the 40th percentile of 52 infectious disease providers in Rhode Island.

See all infectious disease providers in Rhode Island

Medicare billing

Part B allowed, 2024
$26,814
Medicare patients
97
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluconazole14$534

Paid to pharmacies, not to this prescriber.

Other infectious disease in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →